Helicon programmes in oncology
Work directed at intracellular regulators in solid tumours, where the biology is well defined and the current options are exhausted early.
Innovation
Our programs
We are advancing an array of programs with the potential to make a meaningful difference for patients affected by serious diseases. The company has pioneered a new class of alpha-helical peptides — Helicons™ — capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines.
A defined structural class
Helicons™ are engineered alpha-helical peptides — a short stretch of helical structure stabilised so that it holds its shape outside and inside the cell.
Proteins inside the cell
Their job is to reach intracellular proteins and change how those proteins behave, rather than blocking a receptor on the cell surface.
Targets once called undruggable
That is the point of the platform: protein–protein interactions and intracellular regulators that conventional small molecules and antibodies have struggled to engage.
Programmes
IndexHelicon programmes in cardiology
Exploring whether the same structural approach can address remodelling pathways that surface-receptor medicines have left untouched.
Platform & enabling science
Helix stabilisation, intracellular delivery and the assay work that decides whether a target is genuinely reachable.
Programme lines are placeholders — tell us which Helicons™ programmes you want listed and how they should be described.
The class is new. So is the list of targets it opens.
If you work on an intracellular target that has resisted conventional approaches, that is exactly the conversation we want to have.